| Literature DB >> 33332284 |
Camille-Charlotte Balança1, Anna Salvioni1, Clara-Maria Scarlata1,2, Marie Michelas1, Carlos Martinez-Gomez1,3, Carlos Gomez-Roca1,4, Victor Sarradin1,4, Marie Tosolini5, Carine Valle5, Frédéric Pont5, Gwénaël Ferron3, Laurence Gladieff4, Sébastien Vergez6,7, Agnès Dupret-Bories3, Eliane Mery8, Philippe Rochaix8, Jean-Jacques Fournié1, Jean-Pierre Delord1,4,7, Christel Devaud1, Alejandra Martinez1,3, Maha Ayyoub1,2,7.
Abstract
Tumor antigen-specific CD4 T cells accumulate at tumor sites, evoking their involvement in antitumor effector functions in situ. Contrary to CD8 cytotoxic T lymphocyte exhaustion, that of CD4 T cells remains poorly appreciated. Here, using phenotypic, transcriptomic, and functional approaches, we characterized CD4 T cell exhaustion in patients with head and neck, cervical, and ovarian cancer. We identified a CD4 tumor-infiltrating lymphocyte (TIL) population, defined by high PD-1 and CD39 expression, which contained high proportions of cytokine-producing cells, although the quantity of cytokines produced by these cells was low, evoking an exhausted state. Terminal exhaustion of CD4 TILs was instated regardless of TIM-3 expression, suggesting divergence with CD8 T cell exhaustion. scRNA-Seq and further phenotypic analyses uncovered similarities with the CD8 T cell exhaustion program. In particular, PD-1hiCD39+ CD4 TILs expressed the exhaustion transcription factor TOX and the chemokine CXCL13 and were tumor antigen specific. In vitro, PD-1 blockade enhanced CD4 TIL activation, as evidenced by increased CD154 expression and cytokine secretion, leading to improved dendritic cell maturation and consequently higher tumor-specific CD8 T cell proliferation. Our data identify exhausted CD4 TILs as players in responsiveness to immune checkpoint blockade.Entities:
Keywords: Cancer immunotherapy; Immunology; T cells
Mesh:
Substances:
Year: 2021 PMID: 33332284 PMCID: PMC7934837 DOI: 10.1172/jci.insight.142513
Source DB: PubMed Journal: JCI Insight ISSN: 2379-3708